Chloride voltage-gated channel 7 (CLCN7) mutant messenger RNA (CLCN7 mutant mRNA)

Chloride voltage-gated channel 7 (CLCN7) mutant messenger RNA is a therapeutic target for the treatment of osteopetrosis, particularly the autosomal dominant type 2 (ADO2) (Capulli et al., 2015, Nature Communications). The CLCN7 gene encodes a chloride/proton exchanger that is critical for the acidification of the resorption lacuna by osteoclasts, a process necessary for bone matrix degradation (UniProt P51798). In ADO2, missense mutations in one allele exert a dominant-negative effect on the wild-type protein, leading to impaired osteoclast function, increased bone density, and skeletal fragility (Maurizi et al., 2019, Bone Research). Targeting the mutant mRNA specifically using antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs) aims to degrade the defective transcript while sparing the wild-type mRNA (Pellegrini et al., 2018, Molecular Therapy Nucleic Acids). This approach restores sufficient chloride channel activity to normalize bone resorption. Experimental therapies have demonstrated the potential to reduce bone mass and improve bone quality in animal models of the disease (Del Fattore et al., 2008, Journal of Bone and Mineral Research). Challenges include ensuring allele-specificity to avoid silencing the healthy allele and achieving effective delivery to the bone microenvironment.

Other names

CLC-7 mutant mRNAChloride channel 7 mutant mRNACLCN7 mutant transcript

Allele-specific knockdown of mutant mRNA via RNase H-mediated degradation or RNA interference to eliminate dominant-negative effects and restore wild-type protein function (Capulli et al., 2015).